Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma

ClinicalTrials.gov ID: NCT00650923

Public ClinicalTrials.gov record NCT00650923. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 14, 2026, 3:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Trial of Aflibercept (VEGF Trap) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Malignant Glioma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase I trial is studying the side effects and best dose of aflibercept when given together with radiation therapy and temozolomide in treating patients with newly diagnosed or recurrent glioblastoma multiforme, gliosarcoma, or other malignant glioma. Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving aflibercept together with radiation therapy and temozolomide may kill more tumor cells.

Study identification

NCT ID: NCT00650923
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: National Cancer Institute (NCI); NIH
Enrollment: 61 participants

Conditions and interventions

Conditions

Interventions

Drug · Procedure

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 30, 2008
Primary completion: May 31, 2013
Completion: Nov 30, 2013
Last update posted: May 29, 2014

2008 – 2013

United States locations

U.S. sites: 9
U.S. states: 6
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of California at Los Angeles (UCLA )	Los Angeles	California	90095	—
UCSF-Mount Zion	San Francisco	California	94115	—
University of California San Francisco Medical Center-Parnassus	San Francisco	California	94143	—
Adult Brain Tumor Consortium	Baltimore	Maryland	21231-1000	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02115	—
Massachusetts General Hospital	Charlestown	Massachusetts	02129	—
Memorial Sloan-Kettering Cancer Center	New York	New York	10065	—
University of Pittsburgh	Pittsburgh	Pennsylvania	15232	—
M D Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00650923, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 29, 2014 · Synced Sep 14, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00650923 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →